RxDoctor Payments Data

Mark Lawton, MD

Cardiovascular Disease · Hilton Head, SCNPI 1497707053

Payments from drug & device makers

$6,790in general payments, 2019–2025

Across 201 payments — averaging $33.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$1K
  • Abiomed$888
  • Boston Scientific$576
  • Atricure, Inc.$329
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$311
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$96414%
  • Food & beverage$5,81486%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,790 in reported general payments places this provider in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$223,509
Medicare patients
1,019
Services billed
2,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$181,488
EntrestoSacubitril/Valsartan32$49,136
XareltoRivaroxaban34$39,464
Repatha SureclickEvolocumab16$17,125
BrilintaTicagrelor18$14,042
Nebivolol Hcl41$2,747
Metoprolol Succinate137$2,377
Valsartan47$1,128
Rosuvastatin Calcium44$947
Losartan Potassium92$902
ClopidogrelClopidogrel Bisulfate46$818
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$808
Atorvastatin Calcium70$744
Carvedilol75$657
Metoprolol Tartrate66$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$181,488167 claims
NovartisEntresto$157$49,13632 claims
Johnson & JohnsonXarelto$148$39,46434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Hilton Head

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →